A Phase 3 interventional study of Placebo and tadalafil in Benign Prostatic Hyperplasia, sponsored by Eli Lilly and Company. Completed at 27 sites in 5 countries. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2010-11-17.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.
Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one is the 10th largest by enrollment, is one of 5 that started in 2009, is one of 10 in phase 3, and was the 6th registered.
828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
Browse Prostatic Hyperplasia studies →2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:
Beni-Suef University · Sites in Egypt
Ages 50+ · Men only
Assiut University
Men only
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 45 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 11 · Phase 4 6
First in 2004; this study’s year is marked. 5 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 325 is above the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 258 across the 26 interventional studies. Of the 23 that completed or were terminated, 15 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 26 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
17 studies in Prostatic Hyperplasia by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 17 finished, 16 (94%) have results posted.
Among the 17 studies in Prostatic Hyperplasia by Eli Lilly and Company, this one is the 10th largest by enrollment, is one of 5 that started in 2009, is one of 9 in phase 3, and was the 6th registered.
Eli Lilly and Company’s Prostatic Hyperplasia studies by the year they started, since 2004.
1 of the studies testing tadalafil in Prostatic Hyperplasia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07654413Beni-Suef UniversityTamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies testing tadalafil in Prostatic Hyperplasia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 17 in Prostatic Hyperplasia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether an experimental drug known as tadalafil given once daily can reduce the symptoms associated with Benign Prostatic Hyperplasia (straining, urinary frequency, feeling like your bladder is still full, etc.)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: tadalafil
Drug: Placebo
Following a 4-week placebo lead-in period, subjects received placebo tablet by mouth once daily over a 12-week period.
Following a 4-week placebo lead-in period, subjects received tadalafil 5 mg tablet by mouth once daily over a 12-week period.
Also known as: Cialis, LY450190
Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS)
The IPSS Total Score is obtained by combining the scores of the responses to Question 1 through Question 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline to 4 Weeks, Benign Prostatic Hyperplasia (BPH) Impact Index
The BPH Impact Index (BII) is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range from 0 to 13; higher scores represent increased perceived impact of benign prostatic hyperplasia-lower urinary tract symptoms on overall health. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 4 weeks
Change From Baseline to 12 Weeks, Benign Prostatic Hyperplasia (BPH) Impact Index
The BII is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range from 0 to 13; higher scores represent increased perceived impact of benign prostatic hyperplasia-lower urinary tract symptoms on overall health. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore
IPSS irritative subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 0 (few irritative symptoms) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore
IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (few obstructive symptoms) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Nocturia Question
Measures nocturia (the need to get up at night to urinate). Scores range from 0 (few episodes of nocturia) to 5 (frequent episodes of nocturia). LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index
Assessment of QoL by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible). LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Patient Global Impression of Improvement (PGI-I), Number of Participants in 7 Response Categories
A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse).
Time frame: 12 weeks
Clinical Global Impression of Improvement (CGI-I), Number of Participants in 7 Response Categories
Measures clinician's perception of patient improvement at the time of assessment compared with the start of treatment. Scores range from 1 (very much better) to 7 (very much worse).
Time frame: 12 weeks
Change From Baseline to 1 Week, International Prostate Symptom Score (IPSS)
The IPSS Total Score is obtained by combining the scores of the responses to Question 1 through Question 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 1 week
Change From Baseline to 4 Weeks, International Prostate Symptom Score (IPSS)
The IPSS Total Score is obtained by combining the scores of the responses to Question 1 through Question 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 4 Weeks
Change From Baseline to 12 Weeks, International Index of Erectile Function (IIEF)- Erectile Function (EF) Domain Scores
Self-reported EF. Scores range from 0 (low or no EF) to 5 (high EF) on 6 questions (1-5, 15 of the IIEF). EF Domain scores range from 0 to 30. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.
Time frame: Baseline, 12 weeks
Change From Baseline to 12 Weeks, Peak Flow Rate (Qmax) by Uroflowmetry
Qmax was defined as the peak urine flow rate (measured in milliliters per second \[mL/sec\] using standard calibrated flowmeter). At each visit, a uroflowmetry assessment was considered valid and the data were included in the statistical analyses only if the prevoid total bladder volume (assessed by ultrasound) was \>=150 to \<=550 milliliters (mL) and the voided volume (Vcomp) was \>=125 mL.
Time frame: Baseline, 12 weeks
Change From Baseline to 12 Weeks, Mean Flow Rate (Qmean) by Uroflowmetry
Qmean was defined as the mean urine flow rate (measured in mL/sec using standard calibrated flowmeter). At each visit, a uroflowmetry assessment was considered valid and the data were included in the statistical analyses only if the prevoid total bladder volume (assessed by ultrasound) was \>=150 to \<=550 mL and the Vcomp was \>=125 mL.
Time frame: Baseline, 12 weeks
Change From Baseline to 12 Weeks, Voided Volume (Vcomp) by Uroflowmetry
Vcomp was defined as the volume of urine voided (measured in mL using standard calibrated flowmeter). At each visit, a uroflowmetry assessment was considered valid and the data were included in the statistical analyses only if the prevoid total bladder volume (assessed by ultrasound) was \>=150 to \<=550 mL and the Vcomp was \>=125 mL.
Time frame: Baseline, 12 weeks
Change From Baseline to 12 Weeks, Postvoid Residual (PVR) Volume
The amount of urine remaining in the bladder after void completion.
Time frame: Baseline, 12 weeks
| Milestone | Tadalafil | Placebo |
|---|---|---|
| Started | 161 | 164 |
| Completed | 148 | 152 |
| Not completed | 13 | 12 |
| Withdrew: Withdrawal by subject | 2 | 4 |
| Withdrew: Protocol violation | 1 | 3 |
| Withdrew: Lost to follow-up | 0 | 3 |
| Withdrew: Adverse event excluding death | 2 | 1 |
| Withdrew: Entry criteria not met | 4 | 1 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 |
The IPSS Total Score is obtained by combining the scores of the responses to Question 1 through Question 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.
| Units on a Scale | Tadalafil | Placebo |
|---|---|---|
| Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) | -5.6 ± 0.47 | -3.6 ± 0.47 |
The BPH Impact Index (BII) is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range from 0 to 13; higher scores represent increased perceived impact of benign prostatic hyperplasia-lower urinary tract symptoms on overall health. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.
| Units on a Scale | Tadalafil | Placebo |
|---|---|---|
| Change From Baseline to 4 Weeks, Benign Prostatic Hyperplasia (BPH) Impact Index | -1.8 ± 0.18 | -1.2 ± 0.18 |
The BII is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range from 0 to 13; higher scores represent increased perceived impact of benign prostatic hyperplasia-lower urinary tract symptoms on overall health. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.
| Units on a Scale | Tadalafil | Placebo |
|---|---|---|
| Change From Baseline to 12 Weeks, Benign Prostatic Hyperplasia (BPH) Impact Index | -1.8 ± 0.21 | -1.3 ± 0.21 |
IPSS irritative subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 0 (few irritative symptoms) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.
| Units on a Scale | Tadalafil | Placebo |
|---|---|---|
| Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore | -2.3 ± 0.22 | -1.3 ± 0.21 |
IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (few obstructive symptoms) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.
| Units on a Scale | Tadalafil | Placebo |
|---|---|---|
| Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore | -3.3 ± 0.31 | -2.3 ± 0.31 |
Measures nocturia (the need to get up at night to urinate). Scores range from 0 (few episodes of nocturia) to 5 (frequent episodes of nocturia). LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.
| Units on a Scale | Tadalafil | Placebo |
|---|---|---|
| Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Nocturia Question | -0.5 ± 0.08 | -0.4 ± 0.08 |
Assessment of QoL by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible). LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.
| Units on a Scale | Tadalafil | Placebo |
|---|---|---|
| Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index | -1.0 ± 0.10 | -0.7 ± 0.10 |
A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse).
| Participants | Tadalafil | Placebo |
|---|---|---|
| 7-Very Much Worse | 1 | 0 |
| 6-Much Worse | 5 | 6 |
| 5-A Little Worse | 4 | 4 |
| 4-No Change | 30 | 57 |
| 3-A Little Better | 57 | 53 |
| 2-Much Better | 46 | 32 |
| 1-Very Much Better | 12 | 6 |
Measures clinician's perception of patient improvement at the time of assessment compared with the start of treatment. Scores range from 1 (very much better) to 7 (very much worse).
| Participants | Tadalafil | Placebo |
|---|---|---|
| 7-Very Much Worse | 0 | 0 |
| 6-Much Worse | 5 | 2 |
| 5-A Little Worse | 4 | 10 |
| 4-No Change | 36 | 59 |
| 3-A Little Better | 58 | 55 |
| 2-Much Better | 39 | 25 |
| 1-Very Much Better | 13 | 7 |
The IPSS Total Score is obtained by combining the scores of the responses to Question 1 through Question 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.
| Units on a Scale | Tadalafil | Placebo |
|---|---|---|
| Change From Baseline to 1 Week, International Prostate Symptom Score (IPSS) | -3.4 ± 0.35 | -2.7 ± 0.35 |
The IPSS Total Score is obtained by combining the scores of the responses to Question 1 through Question 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.
| Units on a Scale | Tadalafil | Placebo |
|---|---|---|
| Change From Baseline to 4 Weeks, International Prostate Symptom Score (IPSS) | -5.3 ± 0.43 | -3.5 ± 0.43 |
Self-reported EF. Scores range from 0 (low or no EF) to 5 (high EF) on 6 questions (1-5, 15 of the IIEF). EF Domain scores range from 0 to 30. LS mean of change from baseline to endpoint is from an ANCOVA. The model includes terms for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction and treatment-by-region interaction.
| Units on a Scale | Tadalafil | Placebo |
|---|---|---|
| Change From Baseline to 12 Weeks, International Index of Erectile Function (IIEF)- Erectile Function (EF) Domain Scores | 6.7 ± 0.80 | 2.0 ± 0.82 |
Qmax was defined as the peak urine flow rate (measured in milliliters per second \[mL/sec\] using standard calibrated flowmeter). At each visit, a uroflowmetry assessment was considered valid and the data were included in the statistical analyses only if the prevoid total bladder volume (assessed by ultrasound) was \>=150 to \<=550 milliliters (mL) and the voided volume (Vcomp) was \>=125 mL.
| mL/sec | Tadalafil | Placebo |
|---|---|---|
| Change From Baseline to 12 Weeks, Peak Flow Rate (Qmax) by Uroflowmetry | 1.6 ± 4.64 | 1.1 ± 4.64 |
Qmean was defined as the mean urine flow rate (measured in mL/sec using standard calibrated flowmeter). At each visit, a uroflowmetry assessment was considered valid and the data were included in the statistical analyses only if the prevoid total bladder volume (assessed by ultrasound) was \>=150 to \<=550 mL and the Vcomp was \>=125 mL.
| mL/sec | Tadalafil | Placebo |
|---|---|---|
| Change From Baseline to 12 Weeks, Mean Flow Rate (Qmean) by Uroflowmetry | 0.6 ± 2.93 | 0.5 ± 2.79 |
Vcomp was defined as the volume of urine voided (measured in mL using standard calibrated flowmeter). At each visit, a uroflowmetry assessment was considered valid and the data were included in the statistical analyses only if the prevoid total bladder volume (assessed by ultrasound) was \>=150 to \<=550 mL and the Vcomp was \>=125 mL.
| mL | Tadalafil | Placebo |
|---|---|---|
| Change From Baseline to 12 Weeks, Voided Volume (Vcomp) by Uroflowmetry | 16.9 ± 88.74 | 3.9 ± 105.68 |
The amount of urine remaining in the bladder after void completion.
| mL | Tadalafil | Placebo |
|---|---|---|
| Change From Baseline to 12 Weeks, Postvoid Residual (PVR) Volume | 8.8 ± 56.40 | 4.5 ± 66.71 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tadalafil | — | 2/161 (1.2%) | 41/161 (25.5%) |
| Placebo | — | 0/164 (0%) | 36/164 (22%) |
| Event | Tadalafil | Placebo |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 1/161 | 0/164 |
| EndocarditisInfections and infestations | 1/161 | 0/164 |
| Event | Tadalafil | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 6/161 | 1/164 |
| Back painMusculoskeletal and connective tissue disorders | 5/161 | 4/164 |
| NasopharyngitisInfections and infestations | 3/161 | 3/164 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/161 | 0/164 |
| DizzinessNervous system disorders | 3/161 | 0/164 |
| HypertensionVascular disorders | 3/161 | 3/164 |
| InfluenzaInfections and infestations | 1/161 | 3/164 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 2/161 | 0/164 |
| SinusitisInfections and infestations | 2/161 | 0/164 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/161 | 0/164 |
| Age Continuous(years) | Tadalafil | Placebo | Total |
|---|---|---|---|
| Mean | 65.1 ± 8.43 | 64.6 ± 10.03 | 64.9 ± 9.26 |
| Sex: Female, Male(Participants) | Tadalafil | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 161 | 164 | 325 |
| Ethnicity (NIH/OMB)(Participants) | Tadalafil | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 46 | 44 | 90 |
| Not Hispanic or Latino | 115 | 120 | 235 |
| Race (NIH/OMB)(Participants) | Tadalafil | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 9 | 8 | 17 |
| Asian | 2 | 0 | 2 |
| Black or African American | 3 | 5 | 8 |
| White | 146 | 150 | 296 |
| More than one race | 1 | 1 | 2 |
| Region of Enrollment(participants) | Tadalafil | Placebo | Total |
|---|---|---|---|
| United States | 50 | 52 | 102 |
| South America | 43 | 43 | 86 |
| Europe | 68 | 69 | 137 |
| Body Mass Index (BMI)(kilogram (kg)/meter (m)^2) | Tadalafil | Placebo | Total |
|---|---|---|---|
| Mean | 27.1 ± 3.82 | 28.4 ± 4.21 | 27.7 ± 4.07 |
| Baseline Lower Urinary Tract Symptoms (LUTS) Severity(participants) | Tadalafil | Placebo | Total |
|---|---|---|---|
| Moderate | 100 | 110 | 210 |
| Severe | 61 | 54 | 115 |
| Peak Urine Flow Rate (Qmax) Category(participants) | Tadalafil | Placebo | Total |
|---|---|---|---|
| <10 mL/sec | 54 | 62 | 116 |
| 10-15 mL/sec | 78 | 67 | 145 |
| >15 mL/sec | 20 | 24 | 44 |
9 further baseline measures are reported on the registry.
The record gives a start of Jan 2009, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2010, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil